IOVA

Iovance Biotherapeutics, Inc. Common Stock

2.54

USD

IOVA Earnings Reports

Positive Surprise Ratio

IOVA beat 20 of 40 last estimates.

50%

Next Report

Date of Next Report

Mar 03, 2026

Estimate for Q4 25 (Revenue/ EPS)

$83.53M

-$0.16

Implied change from Q3 25 (Revenue/ EPS)

+23.83%

-33.33%

Implied change from Q4 24 (Revenue/ EPS)

+13.35%

-38.46%

Iovance Biotherapeutics, Inc. Common Stock earnings per share and revenue

On Nov 06, 2025, IOVA reported earnings of -0.24 USD per share (EPS) for Q3 25, beating the estimate of -0.26 USD, resulting in a 8.81% surprise. Revenue reached 67.45 million, compared to an expected 73.85 million, with a -8.66% difference. The market reacted with a +27.62% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 14 analysts forecast an EPS of -0.16 USD, with revenue projected to reach 83.53 million USD, implying an decrease of -33.33% EPS, and increase of 23.83% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Amgen Inc

Report Date

Feb 03, 2026 For Q4 25

Estimate

$4.82

Actual

$5.29

Surprise

+9.56%

Bristol-Myers Squibb Co.

Report Date

Feb 05, 2026 For Q4 25

Estimate

$1.12

Actual

$1.26

Surprise

+11.88%

GSK plc - ADR

Report Date

Feb 04, 2026 For Q4 25

Estimate

$0.23

Actual

$0.49

Surprise

+111.36%

Biogen Inc. Common Stock

Report Date

Feb 06, 2026 For Q4 25

Estimate

$1.62

Actual

$1.99

Surprise

+22.39%

Illumina Inc

Report Date

Feb 05, 2026 For Q4 25

Estimate

$1.24

Actual

$1.35

Surprise

+8.01%

QIAGEN N.V.

Report Date

Feb 04, 2026 For Q4 25

Estimate

$0.64

Actual

$0.62

Surprise

-3.32%

Bio-Techne Corp.

Report Date

Feb 04, 2026 For Q2 26

Estimate

$0.44

Actual

$0.46

Surprise

+3.95%

Arrowhead Research Corporation

Report Date

Feb 05, 2026 For Q1 26

Estimate

$0.25

Actual

$0.22

Surprise

-14.76%

Immunovant, Inc. Common Stock

Report Date

Feb 06, 2026 For Q3 26

Estimate

-$0.72

Actual

-$0.61

Surprise

+16.27%

Adaptive Biotechnologies Corporation Common Stock

Report Date

Feb 05, 2026 For Q4 25

Estimate

-$0.18

Actual

-$0.09

Surprise

+51.33%

FAQ

What were Iovance Biotherapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, Iovance Biotherapeutics, Inc. Common Stock reported EPS of -$0.24, beating estimates by 8.81%, and revenue of $67.45M, -8.66% below expectations.

How did the market react to Iovance Biotherapeutics, Inc. Common Stock's Q3 2025 earnings?

The stock price moved up 27.62%, changed from $1.81 before the earnings release to $2.31 the day after.

When is Iovance Biotherapeutics, Inc. Common Stock expected to report next?

The next earning report is scheduled for Mar 03, 2026.

What are the forecasts for Iovance Biotherapeutics, Inc. Common Stock's next earnings report?

Based on 14 analysts, Iovance Biotherapeutics, Inc. Common Stock is expected to report EPS of -$0.16 and revenue of $83.53M for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.